Related Experiment Video
Updated: Aug 13, 2025

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
P-21 Activated Kinases in Liver Disorders
Xun Qiu1,2, Hanzhi Xu1,2, Kai Wang1,3
1Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Abstract:
The p21 Activated Kinases (PAKs) are serine threonine kinases and play important roles in many biological processes, including cell growth, survival, cytoskeletal organization, migration, and morphology. Recently, PAKs have emerged in the process of liver disorders, including liver cancer, hepatic ischemia-reperfusion injury, hepatitis, and liver fibrosis, owing to their effects in multiple signaling pathways in various cell types. Activation of PAKs promotes liver cancer growth and metastasis and contributes to the resistance of liver cancer to radiotherapy and chemotherapy, leading to poor survival of patients. PAKs also play important roles in the development and progression of hepatitis and other pathological processes of the liver such as fibrosis and ischemia-reperfusion injury. In this review, we have summarized the currently available studies about the role of PAKs in liver disorders and the mechanisms involved, and further explored the potential therapeutic application of PAK inhibitors in liver disorders, with the aim to provide a comprehensive overview on current progress and perspectives of PAKs in liver disorders.
Insights
p21 Activated Kinases (PAKs) are crucial in liver disorders like cancer and fibrosis. Inhibiting PAKs may offer new therapeutic strategies for these conditions.
Area of Science:
- Molecular Biology
- Hepatology
- Oncology
Background:
- p21 Activated Kinases (PAKs) are serine/threonine kinases regulating cell growth, survival, and migration.
- PAKs are increasingly implicated in various liver pathologies, including cancer, fibrosis, and ischemia-reperfusion injury.
Purpose of the Study:
- To review the role of PAKs in liver disorders.
- To explore the mechanisms underlying PAK involvement in liver diseases.
- To discuss the therapeutic potential of PAK inhibitors in liver conditions.
Main Methods:
- Literature review of studies on PAKs in liver disorders.
- Analysis of signaling pathways affected by PAKs in liver cells.
- Evaluation of preclinical and clinical data on PAK inhibitors.
Main Results:
- PAKs promote liver cancer growth, metastasis, and resistance to therapy.
- PAKs are involved in the pathogenesis of hepatitis, liver fibrosis, and ischemia-reperfusion injury.
- PAK activation influences multiple signaling pathways in diverse liver cell types.
Conclusions:
- PAKs are significant contributors to liver disease progression.
- Targeting PAKs with inhibitors presents a promising therapeutic avenue for liver disorders.
- Further research is warranted to fully elucidate PAK functions and optimize inhibitor strategies.
Related Concept Videos
cAMP-dependent Protein Kinase Pathways
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
MAPK Signaling Cascades
The JAK-STAT Signaling Pathway

